InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,447.87
(
-0.31%
)
US TECH 100
18,978.00
(
-1.19%
)
Dow Jones
39,411.21
(
0.67%
)
Brent Oil
85.31
(
0.05%
)
Bitcoin
60,280.47
(
0.03%
)
Post# of 252335
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: None

Wednesday, 05/23/2012 4:08:16 PM

Wednesday, May 23, 2012 4:08:16 PM

Post# of 252335
CLDX PR:

Key quotes for this interim look:

In addition, in patients with triple negative breast cancer who also highly express GPNMB, greater activity was observed (CDX-011 ORR of 36%; IC ORR of 0%)



In patients with both triple negative breast cancer and high GPNMB expression, a statistically significant PFS benefit is currently observed (p=0.0032)



(Caution these subgroup numbers are very small).

Not slam-dunk results, but pretty intriguing - stock is down a bit AH so who knows what the market was hoping for.

http://ir.celldextherapeutics.com/phoenix.zhtml?c=93243&p=irol-newsArticle&ID=1699241&highlight=
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up